Anti-TNF Falters After Prior Non-Anti-TNF Biologic, Especially in Ulcerative Colitis

This propensity-matched registry analysis quantifies reduced durability and remission of anti-tumour necrosis factor (anti-TNF) therapy when positioned after a biologic with a different mechanism of action, informing sequencing decisions pharmacists help make.

anti-TNFinfliximabadalimumabgolimumabustekinumabvedolizumabinflammatory bowel diseaseCrohn's diseaseulcerative colitistreatment sequencingbiologicsENEIDA registrypropensity score matchingreal-world evidence Clinical Practice

Background Information

Anti-TNF therapy is less effective after biologics with different mechanisms.

Understanding the effectiveness of anti-TNF therapy after prior biologic treatment with a different mechanism of action (MOA) is crucial for optimizing treatment strategies in inflammatory bowel disease (IBD). In Crohn's disease (CD), anti-TNF after a different MOA showed a 55% higher risk of discontinuation compared to first-line therapy. In ulcerative colitis (UC), it had significantly lower durability and remission rates. The study indicates that anti-TNF therapies used after biologics with a different MOA may lead to reduced treatment success, particularly in UC, suggesting the need for careful consideration in treatment sequencing. Anti-TNF after a different MOA is less effective and durable, especially in ulcerative colitis.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Yagüe Caballero C, García López S, Royo Esteban A, Figueras Panillo L, Nos P, de Castro L, Martín-Arranz MD, Barreiro-de Acosta M, Ricart E, de Francisco R, Iglesias E, Giordano A, Varela P, Rodríguez-Lago I, Rivero M, Sicilia B, Navarro-Llavat M, Vera I, Suria C, Guardiola J, Barrio J, Calafat M, Gutiérrez A, Calvet X, de la Cruz DR, Mesonero F, Martínez Pascual C, P Gisbert J, Gargallo-Puyuelo CJ, Monfort I Miquel D, Sierra M, Arranz L, Rodríguez-Gutiérrez C, Lorente R, Bermejo F, Márquez-Mosquera L, Torres Vicente G, Pérez-Calle JL, Huguet JM, Ramos L, Ponferrada-Díaz Á, Ceballos D, Diz-Lois Palomares MT, Sesé Abizanda E, Vega P, Pajares R, Santos Fernández J, Betoré E, Busquets D, Merino O, Martínez-Flores C, Zabana Y, Sampedro González MJ, Ortiz de Zarate J, Fuentes Coronel A, Sainz Arnau E, Carpio D, Jiménez N, Marín-Jiménez I, Bujanda L, Camargo Camero R, Irabien M, Abanades Tercero M, Velayos Jiménez B, Robledo Andres P, Trapero AM, Delgado-Guillena PG, Hernández Villalba L, Menacho M, Rull Murillo N, Leal C, Alba C, Gómez Espín R, Lucendo AJ, Van Domselaar M, García Alles L, Iyo Miyashiro E, Crespo Catalá A, Gilabert P, Martín Rodríguez D, Navas-López VM, Calvo Iñiguez M, Ginard D, Martínez Pérez T, Domènech E, Casas Deza D

Citation: Yagüe Caballero C, García López S, Royo Esteban A, et al. Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study. Alimentary pharmacology & therapeutics. 2026. doi:10.1111/apt.70904

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →